Cargando…
Azathioprine as an adjuvant therapy in severe Graves’ disease: a randomized controlled open-label clinical trial
INTRODUCTION: Azathioprine (AZA) interferes with the activation of T and B lymphocytes, which are the main cells involved in the pathogenesis of Graves’ disease (GD). The aim of this study was to investigate the effectiveness of AZA as an adjuvant therapy to antithyroid drugs (ATDs) for moderate and...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319122/ https://www.ncbi.nlm.nih.gov/pubmed/37409226 http://dx.doi.org/10.3389/fendo.2023.1168936 |